Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim… - The Lancet …, 2019 - thelancet.com
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee… - 2019 - scholarworks.gnu.ac.kr
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
[PDF][PDF] Aine O'C
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee… - 2019 - bktimes.net
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim… - The Lancet …, 2019 - s-space.snu.ac.kr
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee… - 2019 - scholarworks.bwise.kr
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee… - The Lancet …, 2019 - Elsevier
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
[引用][C] Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim… - The Lancet …, 2019 - cir.nii.ac.jp
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer:
results from the dose escalation and dose expansion parts of a first-in-human, open-label …
results from the dose escalation and dose expansion parts of a first-in-human, open-label …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim… - The Lancet …, 2019 - europepmc.org
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
[PDF][PDF] Aine O'C
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee… - 2019 - bktimes.net
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim… - The Lancet …, 2019 - snucm.elsevierpure.com
Background: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …